DK1341533T3 - Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme - Google Patents

Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme

Info

Publication number
DK1341533T3
DK1341533T3 DK01996377T DK01996377T DK1341533T3 DK 1341533 T3 DK1341533 T3 DK 1341533T3 DK 01996377 T DK01996377 T DK 01996377T DK 01996377 T DK01996377 T DK 01996377T DK 1341533 T3 DK1341533 T3 DK 1341533T3
Authority
DK
Denmark
Prior art keywords
renin inhibitor
cardiovascular disease
synergistic combinations
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
DK01996377T
Other languages
Danish (da)
English (en)
Inventor
William Hewitt
Daniel Lucius Vasella
Randy Lee Webb
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9903412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1341533(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK1341533T3 publication Critical patent/DK1341533T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
DK01996377T 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme DK1341533T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0028151A GB0028151D0 (en) 2000-11-17 2000-11-17 Combination of organic compounds

Publications (1)

Publication Number Publication Date
DK1341533T3 true DK1341533T3 (da) 2006-05-08

Family

ID=9903412

Family Applications (3)

Application Number Title Priority Date Filing Date
DK01996377T DK1341533T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til cardiovaskulære sygdomme
DK08002401T DK1915993T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjertekarsygdomme
DK05015603T DK1602370T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjerte-kredslöbs-sygdomme

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK08002401T DK1915993T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjertekarsygdomme
DK05015603T DK1602370T3 (da) 2000-11-17 2001-11-15 Synergistiske kombinationer omfattende en renininhibitor til hjerte-kredslöbs-sygdomme

Country Status (31)

Country Link
US (4) US8168616B1 (enExample)
EP (7) EP2305231A1 (enExample)
JP (6) JP2004513920A (enExample)
KR (6) KR101008752B1 (enExample)
CN (4) CN100404024C (enExample)
AT (2) ATE397445T1 (enExample)
AU (2) AU2002223680B2 (enExample)
BR (1) BR0115411A (enExample)
CA (2) CA2763223A1 (enExample)
CY (5) CY1105603T1 (enExample)
CZ (2) CZ305341B6 (enExample)
DE (3) DE60134349D1 (enExample)
DK (3) DK1341533T3 (enExample)
EC (1) ECSP034603A (enExample)
ES (4) ES2308347T3 (enExample)
GB (1) GB0028151D0 (enExample)
HU (2) HU230882B1 (enExample)
IL (3) IL155707A (enExample)
LU (2) LU91563I2 (enExample)
MX (1) MXPA03004358A (enExample)
NL (2) NL300385I1 (enExample)
NO (2) NO334002B1 (enExample)
NZ (6) NZ568764A (enExample)
PL (3) PL400914A1 (enExample)
PT (3) PT1602370E (enExample)
RU (2) RU2310443C2 (enExample)
SG (1) SG135969A1 (enExample)
SI (3) SI1341533T1 (enExample)
SK (1) SK287881B6 (enExample)
WO (1) WO2002040007A1 (enExample)
ZA (1) ZA200303497B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005509631A (ja) * 2001-10-18 2005-04-14 ノバルティス アクチエンゲゼルシャフト Ａｔ１−レセプターアンタゴニストと心臓血管薬から形成される塩
WO2003097098A1 (en) 2002-05-17 2003-11-27 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0212410D0 (en) 2002-05-29 2002-07-10 Novartis Ag Organic compounds
AU2003250858A1 (en) * 2002-06-28 2004-01-19 Novartis Ag Use of organic compounds
AU2003255527A1 (en) * 2002-06-28 2004-01-19 Speedel Pharma Ag Pharmaceutical formulation comprising non-peptide renin inhibitor and surfactant
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
RU2413716C2 (ru) 2003-11-26 2011-03-10 Новартис Аг АМИДЫ δ-АМИНО-γ-ГИДРОКСИ-ω-АРИЛАЛКАНОВОЙ КИСЛОТЫ
GB0327839D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1735270B1 (en) * 2004-01-23 2010-06-30 Novartis Ag Diamino alcohols and their use as renin inhibitors
WO2005070871A2 (en) 2004-01-23 2005-08-04 Speedel Experimenta Ag Amino alcohol derivatives and their activity as renin inhibitors
BRPI0506490A (pt) 2004-01-23 2007-02-13 Speedel Experimenta Ag compostos orgánicos
PE20110121A1 (es) 2004-03-17 2011-02-28 Novartis Ag Composiciones farmaceuticas de aliskiren
AU2005224014B9 (en) * 2004-03-17 2009-08-27 Novartis Ag Use of organic compounds
CA2560195A1 (en) * 2004-03-19 2005-09-29 Speedel Experimenta Ag Organic compounds
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
US20080085914A1 (en) * 2004-10-08 2008-04-10 David Louis Feldman Use Of Organic Compounds
GB0428250D0 (en) * 2004-12-23 2005-01-26 Novartis Ag Organic compounds
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
TW200722424A (en) 2005-03-31 2007-06-16 Speedel Experimenta Ag Substituted piperidines
EP1897879A3 (en) 2005-03-31 2008-06-11 Speedel Experimenta AG 2,4,5-substituted piperidines as renin inhibitors
CN101166523A (zh) * 2005-04-27 2008-04-23 诺瓦提斯公司 治疗动脉粥样硬化的方法
GB0511686D0 (en) * 2005-06-08 2005-07-13 Novartis Ag Organic compounds
CN1732952B (zh) * 2005-09-02 2010-04-07 姚俊华 一种治疗高血压的复方分散片
US8158146B2 (en) 2005-09-28 2012-04-17 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
EP1797885B1 (en) * 2005-09-28 2008-03-26 Teva Pharmaceutical Industries Ltd. Stable combinations of amlodipine besylate and benazepril hydrochloride
AU2006311723A1 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin II receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
AU2007225139A1 (en) * 2006-03-13 2007-09-20 Encysive Pharmaceuticals, Inc. Methods and compositions for treatment of diastolic heart failure
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
TW200831463A (en) * 2006-09-12 2008-08-01 Speedel Experimenta Ag Nitrate esters of aminoalcohols
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
MX2009006340A (es) * 2006-12-15 2009-06-23 Novartis Ag Metodos terapeuticos.
CA2677822A1 (en) * 2007-02-14 2008-08-21 Gilead Colorado, Inc. Antihypertensive drug combination
BRPI0817442A2 (pt) * 2007-09-28 2015-06-16 Novarits Ag Formulações galênicas de composto orgânicos
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
KR101164300B1 (ko) 2008-02-22 2012-07-09 한올바이오파마주식회사 약제학적 제제
WO2009125981A2 (ko) 2008-04-10 2009-10-15 한올제약주식회사 약제학적 제제
WO2009127251A1 (en) * 2008-04-16 2009-10-22 Novartis Ag Combinations comprising a renin inhibitor
US20110117194A1 (en) 2008-04-29 2011-05-19 Hanall Biopharma Co., Ltd. Pharmaceutical formulation containing angiotensin-ii receptor blocker
WO2010024772A1 (en) * 2008-08-29 2010-03-04 Medivir Ab Aspartyl protease inhibitors
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
AU2010226620A1 (en) 2009-03-20 2011-09-22 Novartis Ag Galenical formulations of a fixed dose combination of Valsartan and Aliskiren
CN101926793B (zh) * 2010-08-05 2012-08-15 成都自豪药业有限公司 一种含替米沙坦和阿利吉伦的联合用药物及其制备方法
EP2704706A1 (en) 2011-05-06 2014-03-12 Artskin D.O.O. Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
RU2483750C1 (ru) * 2012-03-19 2013-06-10 Общество с ограниченной ответственностью "СупраГен" Способ лечения больных с острым инфарктом миокарда с подъемом сегмента st
NZ724002A (en) * 2012-05-18 2017-07-28 Luoda Pharma Pty Ltd Liquid formulation comprising propylene glycol and an ace inhibitor
RU2554815C1 (ru) * 2014-06-18 2015-06-27 Общество с ограниченной ответственностью "Нанолек" Гипотензивное средство
EP3174530B1 (de) 2014-07-30 2018-08-29 Merck Patent GmbH Direkt verpressbare polyvinylalkohole
BR112019007954A2 (pt) * 2016-10-27 2019-07-02 Damian Pharma Ag inibidor da aldosterona sintase

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4782043A (en) 1983-06-15 1988-11-01 Merck & Co., Inc. Renin inhibitors containing a C-terminal amide cycle
US4898729A (en) 1983-12-09 1990-02-06 Euroceltique, S.A. Treatment of hypertension, compounds and compositions for antihypertension and diuresis
US4812442A (en) 1984-05-29 1989-03-14 Merck & Co., Inc. Tripeptide renin inhibitors
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
US5594021A (en) 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
SE8802428D0 (sv) * 1988-06-28 1988-06-28 Haessle Ab New compounds
US5268374A (en) 1988-10-04 1993-12-07 Abbott Laboratories Non-peptide renin inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
SG52330A1 (en) 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
EP0438311A3 (en) * 1990-01-19 1992-07-01 Merck & Co. Inc. Di- and tripeptide renin inhibitors
US5182266A (en) * 1990-01-31 1993-01-26 Abbott Laboratories Method for treating renal disease
DK0443983T3 (da) 1990-02-19 1996-03-18 Ciba Geigy Ag Acrylforbindelser
TW201738B (enExample) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
US5821232A (en) 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
KR970005839B1 (ko) 1990-05-11 1997-04-21 화이자 인코포레이티드 상승 치료효과를 얻기 위한 조성물 및 방법
WO1992000972A1 (en) 1990-07-11 1992-01-23 Abbott Laboratories Renin inhibiting compounds
EP0543936A4 (en) * 1990-08-15 1993-06-30 Abbott Laboratories Renin inhibitors
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
JP3398379B2 (ja) 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
WO1992013564A1 (en) 1991-02-06 1992-08-20 Schering Corporation Combination of an angiotensin ii antagonist or renin inhibitor with a neutral endopeptidase inhibitor
CA2061607C (en) 1991-02-21 1999-01-19 Hiroaki Yanagisawa 1-biphenylimidazole derivatives, their preparation and their therapeutic use
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
DE4121975A1 (de) 1991-07-03 1993-01-07 Basf Ag Thermoplastische formmassen auf der basis von polycarbonaten, styrol/acrylnitril-polymerisaten und polyolefinen
US5256667A (en) 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
TW226375B (enExample) 1991-10-24 1994-07-11 American Home Prod
US6057344A (en) 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
RU2130920C1 (ru) 1993-04-27 1999-05-27 Смитклайн Бичам Корпорейшн Производные индана, способ их получения, фармацевтическая композиция и способ антагонизирования эндотелиновых рецепторов
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
ES2154277T3 (es) * 1993-07-15 2001-04-01 Hoffmann La Roche Combinacion farmaceutica que contiene un inhibidor del sistema renina-angiotensina y un antagonista de endotelina.
PT714897E (pt) 1993-08-18 2001-05-31 Banyu Pharma Co Ltd Derivado ciclopenteno heteroaromatico fundido possuindo actividade de antagonista de endotelinas
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5659065A (en) 1994-04-18 1997-08-19 Novartis Corporation Alpha-aminoalkanoic acids and reduction products
US5606078A (en) 1994-04-18 1997-02-25 Ciba-Geigy Corporation 3,5-Disubstituted tetrahydrofuran-2-ones
US5562921A (en) 1994-07-15 1996-10-08 Sherman; Bernard C. Stable solid pharmaceutical compositions containing enalapril maleate
JP3741441B2 (ja) 1994-08-19 2006-02-01 アボツト・ラボラトリーズ エンドセリン・アンタゴニスト
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
TW313568B (enExample) 1994-12-20 1997-08-21 Hoffmann La Roche
EP0805802B1 (en) 1995-01-27 2000-08-16 Rhone-Poulenc Rorer Limited Substituted phenyl compounds as endothelin antagonists
US5846990A (en) 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
JPH0971586A (ja) * 1995-09-07 1997-03-18 Yamanouchi Pharmaceut Co Ltd 新規な二環性縮合イミダゾール誘導体
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
RU2172735C2 (ru) 1995-12-20 2001-08-27 Яманоути Фармасьютикал Ко., Лтд. Арилэтенсульфонамидные производные и фармацевтическая композиция
IT1277737B1 (it) 1995-12-28 1997-11-12 Zambon Spa Derivati tiolici ad attivita' inibitrice delle metallopeptidasi
WO1997027314A1 (fr) 1996-01-23 1997-07-31 Shionogi & Co., Ltd. Processus de production d'analogues d'acide oleanolique par la culture de racine pileuse
JP3345891B2 (ja) 1996-04-04 2002-11-18 萬有製薬株式会社 エンドセリン拮抗薬を含有することを特徴とする心不全治療剤
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.
DE19806438A1 (de) * 1998-02-17 1999-08-19 Basf Ag Neue Carbonsäurederivate mit 5-substituiertem Pyrimidinring, ihre Herstellung und Verwendung
WO1999065500A1 (en) * 1998-06-17 1999-12-23 Bristol-Myers Squibb Company Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
WO2000004862A2 (en) 1998-07-20 2000-02-03 Smithkline Beecham Corporation Bioenhanced formulations comprising eprosartan in oral solid dosage form
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1175246A4 (en) * 1999-03-19 2004-12-15 Brigham & Womens Hospital POSITIVE REGULATION OF NITRIC OXIDE SYNTHASE OF TYPE III ENDOTHELIAL CELLS BY HMG-COA REDUCTASE INHIBITORS
JP2003513913A (ja) 1999-11-09 2003-04-15 ファルマシア コーポレイション 血管傷害に起因する病的変化をアルドステロンアンタゴニストで治療、阻害または予防する方法
US20030114389A1 (en) * 2001-11-13 2003-06-19 Webb Randy Lee Combination of organic compounds
WO2003097098A1 (en) 2002-05-17 2003-11-27 Novartis Ag Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
ATE397147T1 (de) 2002-12-31 2008-06-15 Volkswagen Ag Verfahren zur steuerung einer verbrennungskraftmaschine sowie magerlauffahige verbrennungskraftmaschine

Also Published As

Publication number Publication date
DE60117295D1 (de) 2006-04-20
JP6603757B2 (ja) 2019-11-06
LU92315I2 (fr) 2014-01-27
KR101008752B1 (ko) 2011-01-14
JP2009235107A (ja) 2009-10-15
NO2013019I2 (no) 2013-12-17
CN101264073A (zh) 2008-09-17
CN101264072A (zh) 2008-09-17
IL212075A0 (en) 2011-06-30
CY1114829T1 (el) 2015-11-04
ATE317692T1 (de) 2006-03-15
DE60134349D1 (de) 2008-07-17
NO334002B1 (no) 2013-11-11
GB0028151D0 (en) 2001-01-03
KR20080096715A (ko) 2008-10-31
US9023893B2 (en) 2015-05-05
CY2013045I1 (el) 2015-11-04
KR20030051753A (ko) 2003-06-25
NZ525795A (en) 2005-03-24
CZ299749B6 (cs) 2008-11-12
MXPA03004358A (es) 2003-08-19
HUP0301841A3 (en) 2010-07-28
SG135969A1 (en) 2007-10-29
ES2734523T3 (es) 2019-12-10
CN100404024C (zh) 2008-07-23
EP2305233A1 (en) 2011-04-06
JP6373931B2 (ja) 2018-08-15
HU1400409D0 (hu) 2003-09-29
DK1915993T3 (da) 2013-10-14
SI1915993T1 (sl) 2013-10-30
US8168616B1 (en) 2012-05-01
CN1474690A (zh) 2004-02-11
ES2256335T3 (es) 2006-07-16
KR20080011355A (ko) 2008-02-01
NL301005I2 (nl) 2019-10-29
KR101258365B1 (ko) 2013-04-30
US20120004312A1 (en) 2012-01-05
EP1602370A2 (en) 2005-12-07
JP2018030894A (ja) 2018-03-01
EP1915993B1 (en) 2013-07-10
HK1059212A1 (en) 2004-06-25
EP1341533B1 (en) 2006-02-15
US20120016035A1 (en) 2012-01-19
PT1602370E (pt) 2008-09-10
IL212075A (en) 2013-08-29
JP2013213061A (ja) 2013-10-17
NZ550898A (en) 2008-07-31
CA2428647A1 (en) 2002-05-23
JP6577994B2 (ja) 2019-09-18
EP1602370B1 (en) 2008-06-04
HU230882B1 (hu) 2018-11-29
PL400914A1 (pl) 2012-12-17
WO2002040007A1 (en) 2002-05-23
NL301005I1 (enExample) 2019-09-10
PL361404A1 (en) 2004-10-04
BR0115411A (pt) 2004-08-17
JP2004513920A (ja) 2004-05-13
CA2763223A1 (en) 2002-05-23
NO20032233D0 (no) 2003-05-16
ZA200303497B (en) 2004-04-28
CY1105603T1 (el) 2010-07-28
NO20032233L (no) 2003-05-16
ATE397445T1 (de) 2008-06-15
EP1915993A1 (en) 2008-04-30
CY2013045I2 (el) 2015-11-04
EP2305231A1 (en) 2011-04-06
KR20110063596A (ko) 2011-06-10
JP2017019876A (ja) 2017-01-26
EP1341533A1 (en) 2003-09-10
CZ305341B6 (cs) 2015-08-05
CY2009005I2 (el) 2012-01-25
US8618174B2 (en) 2013-12-31
IL155707A0 (en) 2003-11-23
DK1602370T3 (da) 2008-09-22
KR20080097488A (ko) 2008-11-05
ES2429292T3 (es) 2013-11-14
EP2305232A1 (en) 2011-04-06
ECSP034603A (es) 2003-06-25
NZ568764A (en) 2009-11-27
PT1341533E (pt) 2006-06-30
PL400915A1 (pl) 2012-12-17
US20120010295A1 (en) 2012-01-12
RU2310443C2 (ru) 2007-11-20
RU2006132668A (ru) 2008-03-20
SI1341533T1 (sl) 2006-08-31
IL155707A (en) 2012-02-29
JP2018131465A (ja) 2018-08-23
LU91563I2 (fr) 2009-07-06
NL300385I1 (nl) 2009-07-01
EP1602370A3 (en) 2005-12-14
NZ550897A (en) 2008-03-28
NO2013019I1 (no) 2014-06-02
AU2002223680B2 (en) 2005-04-07
AU2368002A (en) 2002-05-27
DE60117295T2 (de) 2006-08-17
JP6089278B2 (ja) 2017-03-08
EP1930000A1 (en) 2008-06-11
DE122009000021I1 (de) 2009-08-06
SK5842003A3 (en) 2003-11-04
NZ537691A (en) 2007-01-26
KR20100114904A (ko) 2010-10-26
CY1108305T1 (el) 2012-01-25
PL227576B1 (pl) 2017-12-29
US9023894B2 (en) 2015-05-05
NZ550896A (en) 2008-06-30
PT1915993E (pt) 2013-10-14
IL217847A0 (en) 2012-03-29
SI1602370T1 (sl) 2008-10-31
ES2308347T3 (es) 2008-12-01
HK1115544A1 (en) 2008-12-05
HUP0301841A2 (hu) 2003-09-29
HK1089356A1 (en) 2006-12-01
EP2305232B1 (en) 2019-07-17
SK287881B6 (sk) 2012-02-03
RU2346703C2 (ru) 2009-02-20
CY2009005I1 (el) 2012-01-25
CN101091703A (zh) 2007-12-26

Similar Documents

Publication Publication Date Title
DK1915993T3 (da) Synergistiske kombinationer omfattende en renininhibitor til hjertekarsygdomme
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
BR0212042A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, e, uso de um composto
EP1734041A3 (en) Platelet ADP receptor inhibitors
NO20024528L (no) Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
HUP0102255A3 (en) Vla-4 inhibitor omepupa-v, pharmaceutical compositions comprising thereof and their use
DE60042585D1 (de) 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
FI940568L (fi) Anti-inflammatorisina aineina toimivia oksindoli-1-(N-(alkoksikarbonyyli))karboksamideja ja -1-(N-karboksamido)-karboksamideja
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
ITMI931806A0 (it) Composti inibitpri di acil enzima-a-colesterolo-o-acil transferasi ad attivita' terapeutica , loro uso e composizioni farmaceutiche che li contengono
IL136687A0 (en) Pharmaceutical composition for the treatment of multiple sclerosis
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
RU2000128859A (ru) Способ защиты печени от ксенобиотиков в эксперименте
NO20042153L (no) Piperidin-2-on-derivatforbindelser og farmasoytisk sammensetning omfattende samme som aktiv ingrediens
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors